Namzaric

Dementia, Vascular, Dementia, Vascular, Alzheimer's Disease + 3 more
Treatment
4 FDA approvals
20 Active Studies for Namzaric

What is Namzaric

MemantineThe Generic name of this drug
Treatment SummaryMemantine is a medication used to treat Alzheimer's Disease. It was approved by the FDA in 2013 and works differently than other Alzheimer's medications, blocking the effects of the neurotransmitter glutamate which can lead to excessive stimulation in Alzheimer's Disease. Around 36 million people were estimated to have Alzheimer's Disease in 2010, with the number rising to 44 million in 2013. It is predicted that this number will reach 115 million by 2050. In 2013, the G8 dementia summit declared that finding a cure or disease-modifying therapy for Alzheimer's Disease should be a global priority, with the objective of achieving this by 2025.
Namendais the brand name
image of different drug pills on a surface
Namzaric Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Namenda
Memantine
2003
235

Approved as Treatment by the FDA

Memantine, commonly known as Namenda, is approved by the FDA for 4 uses like Alzheimer's Disease and moderate Alzheimer's Type Dementia .
Alzheimer's Disease
Used to treat moderate Alzheimer's Type Dementia in combination with Donepezil
moderate Alzheimer's Type Dementia
Used to treat moderate Alzheimer's Type Dementia in combination with Donepezil
severe Alzheimer's Type Dementia
Helps manage severe Alzheimer's Type Dementia
Alzheimer's Disease
Helps manage severe Alzheimer's Type Dementia

Effectiveness

How Namzaric Affects PatientsMemantine is a drug used to treat Alzheimer's dementia. It works by reducing the amount of calcium that enters cells when they are overstimulated by a chemical called glutamate. This leads to improved cognition and other positive effects on the central nervous system. At higher doses, memantine can reduce the ability of neurons to change and learn, but at lower doses it can improve memory and protect neurons from harm. Memantine has low activity with other types of receptors, and does not affect the effects of other drugs used to treat Alzheimer's.
How Namzaric works in the bodyGlutamate, a molecule found in the brain, can overactivate certain receptors and cause toxic effects. Memantine works by blocking these receptors and stopping glutamate from interacting with them. This helps to reduce the toxic effects of glutamate. However, it is not yet known if memantine can stop or slow the brain damage caused by Alzheimer's disease.

When to interrupt dosage

The proposed dosage of Namzaric is contingent upon the determined condition, for example Alzheimer's Disease, Alzheimer's Disease and Dementia, Vascular. The quantity of dosage can be found in the table below, based on the technique of delivery (e.g. Kit - Oral or Solution - Oral).
Condition
Dosage
Administration
Alzheimer's Disease
, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg
Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral
Alzheimer's Disease
, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg
Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral
Dementia, Vascular
, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg
Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral
Dementia, Vascular
, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg
Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral
Alzheimer's Disease
, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg
Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral
Alzheimer's Disease
, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg
Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Warnings

Namzaric has one contraindication, so it should not be utilized for any of the conditions mentioned in the following table.Namzaric Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Memantine may interact with Pulse Frequency
There are 20 known major drug interactions with Namzaric.
Common Namzaric Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Memantine.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Memantine.
Antipyrine
Major
The metabolism of Antipyrine can be decreased when combined with Memantine.
Apomorphine
Major
The metabolism of Apomorphine can be decreased when combined with Memantine.
Artemether
Major
The metabolism of Artemether can be decreased when combined with Memantine.
Namzaric Toxicity & Overdose RiskThe toxic dose of memantine for mice is 437-498mg/kg, and for rats is 328-370mg/kg. No evidence of cancer or genetic mutation was found in mice or rats given large doses. No adverse effects on fertility or reproductive performance were observed in rats given 18mg/kg/day, which is nine times the maximum recommended human dose. Pregnant women should only take this drug if the potential benefits outweigh the possible risks to the fetus. It is not known if memantine is passed through breast milk, so nursing mothers should be cautious when taking this drug.

Namzaric Novel Uses: Which Conditions Have a Clinical Trial Featuring Namzaric?

41 active trials are currently being conducted to investigate the potential of Namzaric in treating Alzheimer's Disease, Vascular Dementia, and other forms of Alzheimer's Disease.
Condition
Clinical Trials
Trial Phases
Alzheimer's Disease
3 Actively Recruiting
Phase 3, Phase 2
Alzheimer's Disease
0 Actively Recruiting
Alzheimer's Disease
39 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1
Dementia, Vascular
0 Actively Recruiting
Alzheimer's Disease
0 Actively Recruiting
Dementia, Vascular
0 Actively Recruiting

Namzaric Reviews: What are patients saying about Namzaric?

5Patient Review
1/3/2019
Namzaric for Moderate to Severe Alzheimer's Type Dementia
My mother started taking this a month ago, and we've seen her skills with conversation,alertness, and cognition improve since then. It's not a cure-all by any means, but it's nice to see her happier and more engaged with the world around her. The fact that it comes in one pill is also great, because she has trouble swallowing pills otherwise.
4Patient Review
1/11/2016
Namzaric for Moderate to Severe Alzheimer's Type Dementia
3Patient Review
3/27/2017
Namzaric for Moderate to Severe Alzheimer's Type Dementia
2.3Patient Review
4/4/2017
Namzaric for Moderate to Severe Alzheimer's Type Dementia
Recently, I was diagnosed with Alzheimer's. I'm not entirely sure if this treatment slowed the progression of my symptoms or not. However, I have been having very vivid dreams every night--some of which are actually quite entertaining. Additionally, I've experienced appetite and weight loss; while this hasn't been a huge problem for me yet as I am at a normal weight, I don't want to lose any more weight. Next month, I will start a clinical trial with aducanumab to see if that adds too many side effects.
2.3Patient Review
8/17/2017
Namzaric for Moderate to Severe Alzheimer's Type Dementia
This didn't alleviate my symptoms whatsoever.
2Patient Review
4/21/2017
Namzaric for Moderate to Severe Alzheimer's Type Dementia
I'm not sure yet if this is working or not. I'll have to wait and see.
1Patient Review
5/12/2017
Namzaric for Moderate to Severe Alzheimer's Type Dementia
I was extremely disappointed with this medication. It did nothing to help me and I feel like it's just a way for the pharmaceutical companies to make money.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about namzaric

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Namzaric used for?

"This medication is used to treat moderate to severe confusion related to Alzheimer's disease. It may improve memory, awareness, and the ability to perform daily functions, but it does not cure Alzheimer's disease."

Answered by AI

How long does it take for Namzaric to work?

"In the subset population that was studied, it was found that the combination of NAMENDA XR and donepezil HCl improved cognition by 2.7 units, which is similar to the 2.6 unit improvement observed in the overall study population."

Answered by AI

What kind of drug is Namzaric?

"Namzaric is a drug used to treat moderate to severe dementia in patients who are already taking memantine. It is a combination of an NMDA receptor antagonist and a reversible inhibitor of the enzyme acetylcholinesterase."

Answered by AI

What is the generic name for Namzaric?

"The generic name for this medication is memantine hydrochloride extended-release, and it is available in 7mg/10mg, 14mg/10mg, 21mg/10mg, and 28mg/10mg capsules."

Answered by AI

Clinical Trials for Namzaric

Image of CSMC in Los Angeles, United States.

Photobiomodulation for Alzheimer's Disease

55 - 89
All Sexes
Los Angeles, CA
The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to provide topical heating to elevate tissue temperature for temporary relief of muscle and joint pain, muscle spasm and stiffness associated with arthritis. It also increases blood circulation and relaxes muscle tissue. This device is being used "off-label," meaning it will be used in a way that is different than its cleared use. We want to learn whether this light treatment can improve executive function, and whether it changes certain inflammatory and neurodegeneration related signals in the blood. To do this, we will apply the photobiomodulation device to your forehead. We will also ask you questions and give you cognitive tests before and after light treatment. We will also collect blood samples before and after treatment.
Recruiting
New This Month
CSMCGolnaz Yadollahikhales, MD
Have you considered Namzaric clinical trials? We made a collection of clinical trials featuring Namzaric, we think they might fit your search criteria.Go to Trials
Image of Smith Family Clinic for Genomic Medicine in Huntsville, United States.

Lifestyle Intervention for Alzheimer's Disease

65 - 75
All Sexes
Huntsville, AL
Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced. This study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.
Recruiting
Has No Placebo
Smith Family Clinic for Genomic Medicine
Have you considered Namzaric clinical trials? We made a collection of clinical trials featuring Namzaric, we think they might fit your search criteria.Go to Trials
Have you considered Namzaric clinical trials? We made a collection of clinical trials featuring Namzaric, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security